264 studies found for:    "Emtricitabine"[TREATMENT] AND HIV [CONDITION]
Show Display Options
Rank Status Study
1 Recruiting Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide;   Drug: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
2 Recruiting Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide;   Drug: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
3 Recruiting Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df;   Drug: ritonavir + atazanavir + emtricitabine/tenofovir df
4 Active, not recruiting Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen in HIV 1 Infected, Antiretroviral Treatment-Naive Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/GS-7340;   Drug: elvitegravir/cobicistat/emtricitabine/ tenofovir df
5 Active, not recruiting Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: darunavir/cobicistat/emtricitabine/GS-7340;   Drug: darunavir + cobicistat + emtricitabine/tenofovir df
6 Active, not recruiting Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: GS-9350 + atazanavir + emtricitabine/tenofovir DF;   Drug: Comparator: ritonavir + atazanavir + emtricitabine/tenofovir DF
7 Active, not recruiting Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df;   Drug: ritonavir-boosted protease inhibitor plus Truvada
8 Active, not recruiting Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df;   Drug: NNRTI plus FTC/TDF
9 Active, not recruiting Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Intervention: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df
10 Recruiting Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
Conditions: HIV;   HIV Infections
Intervention: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
11 Not yet recruiting Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects
Conditions: HIV;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide;   Drug: E/C/F/TDF, EFV/FTC/TDF, ritonavir + atazanavir + FTC/TDF, or GS-9350 + atazanavir + FTC/TDF
12 Withdrawn Raltegravir Activity In Lymphoid Tissues
Conditions: HIV Infection;   HIV Infections
Interventions: Drug: Efavirenz + Tenofovir DF/Emtricitabine;   Drug: Raltegravir + Tenofovir DF/Emtricitabine;   Procedure: Colonoscopy with biopsies;   Procedure: Inguinal Lymph Node Excision
13 Recruiting Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Intervention: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df
14 Completed An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects
Condition: HIV Infections
Intervention: Drug: Emtricitabine
15 Recruiting Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)
Conditions: HIV;   HIV Infections
Interventions: Drug: emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line);   Drug: abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line);   Drug: emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
16 Completed
Has Results
ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Drug: Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz);   Drug: Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV);   Drug: Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
17 Recruiting Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)
Condition: HIV Infection
Interventions: Drug: Tenofovir, Emtricitabine, Lopinavir/r;   Drug: Tenofovir, Emtricitabine, Raltegravir
18 Active, not recruiting Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults.
Condition: HIV-1 Infection
Interventions: Drug: emtricitabine/rilpivirine/tenofovir disoproxil fumarate;   Drug: efavirenz/emtricitabine/tenofovir disoproxil fumarate
19 Completed PK of Tenofovir, Emtricitabine and Efavirenz in Healthy Volunteers
Conditions: HIV Infection;   HIV Infections
Intervention: Drug: Atripla®
20 Unknown  Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine
Condition: HIV Infections
Interventions: Drug: Raltegravir;   Drug: Maraviroc;   Drug: Tenofovir/Emtricitabine

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years